Global Markets for Infectious Disease Treatments

  • May 2013
  • -
  • BCC Research
  • -
  • 183 pages

STUDY GOALS AND OBJECTIVES

Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and our attempts to control these diseases have met with great success. Diseases that were once death sentences are now chronic and manageable diseases.

But as with every ongoing story, microbes have transformed themselves to outwit current medications, and the battle to rid humans of the most virulent of diseases continues. With the constant combining and reinvention of microbes comes an urgent need for improved antibiotic and viral medications to sustain the progress made in addressing the most aggressive of infectious diseases.

Under these circumstances, there is need for a current and comprehensive report on infectious diseases covering diagnosis, treatment, demand trends, opportunities, and emerging technologies.

This study gives a clear, quantitative picture of the supply-and-demand scenario, and it highlights the technological and investment opportunities in the field.

REASONS FOR DOING THE STUDY

This report provides the reader with a detailed analysis of the global infectious disease market, with emphasis on seven major infectious diseases (i.e., human immunodeficiency virus/acquired immunodeficiency virus [HIV/AIDS]; hepatitis A, B, C; malaria, rotavirus/diarrhea; measles; pneumonia; and tuberculosis [TB]).

The report also discusses technological developments, future trends, and emerging opportunities. The major objectives of this study are:

• Assessing the current state of infectious diseases on a global basis.
• Identifying the driving factors for demand of new diagnostic and pharmaceutical products.
• Estimating current and future market sizes for diagnostic and pharmaceutical infectious disease products.
• Estimating the current global supply-and-demand scenario, by disease type and geographical regions.
• Identifying factors that influence the industry and proposing market opportunities.

SCOPE OF REPORT

The market report organizes information from diverse sources into a cohesive unit that includes an overview, global implications of infectious diseases, infectious diseases by type, treatment and prevention, emerging pharmaceutical and diagnostic products, and an applicable patents section. Information is organized by type of infectious disease (i.e., bacterial, viral, parasitic) and appropriate treatments, both current and anticipated.

INTENDED AUDIENCE

This updated version on the infectious disease market and technologies will be a valuable tool for decision makers and manufacturers in both the diagnostic and the pharmaceutical treatment industries. Individuals at research foundations, manufacturing companies, and university laboratories will find valuable information on the global diagnostic product and pharmaceutical industries. This information will also be useful for individuals involved in strategic planning and marketing and sales development.

The audience will obtain a broad view of the social and economic consequences of infectious diseases. Additionally, emphasis on the type of disease, major players in the marketplace, market conditions, and current and projected revenues will be provided.

METHODOLOGIES AND INFORMATION SOURCES

The data for this report were gathered from primary and secondary sources. Sources include information obtained from industry analysis, manufacturers, academic and trade journals, and industry associations. Additional sources include the U.S. Patent and Trademark Office (USPTO), U.S. Securities and Exchange Commission (SEC) filings, the World Health Organization (WHO), the Centers for Disease Control (CDC), the Mayo Clinic, the Pharmaceutical Research and Manufacturing Association, and UNAIDS.

Where precise information was not available, a projection was made using reasonable assumptions and estimates based on historical data. All market data are based on manufacturers’ sales.

ANALYST CREDENTIALS

Peggy Lehr is the BCC Research analyst for this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and an MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor, and publisher within the publishing industry for both for-profit and not-for-profit organizations. She is the author of several BCC reports dealing with healthcare, pharmaceuticals, and agriculture.

REPORT HIGHLIGHTS

This report provides:

• An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
• Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
• Examination of technological developments, future trends, and emerging opportunities
• Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region
• Patent analysis
• Comprehensive company profiles of major players.

Table Of Contents

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 3
METHODOLOGIES AND INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ON-LINE SERVICES 4
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 ($ MILLIONS) 7
SUMMARY FIGURE PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE
DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC
REGION, 2012 AND 2017 (%)
8

CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES, AND TREATMENT 10

TOP GLOBAL CAUSES OF DEATH 10
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME
LEVEL (%) 11
MAJOR INFECTIOUS DISEASES 11
TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER
OF CASES, TREATMENT OPTIONS) 11
HISTORICAL IMPACT OF INFECTIOUS DISEASES 12
LEADING CAUSES OF GLOBAL DEATHS 13
Transmission of Infectious Diseases 13
LINKING INFECTIOUS DISEASE TO CANCER 13
TREATMENTS FOR INFECTIOUS DISEASES 13
PREVENTION 13
VACCINATION 14
FIGURE 1 VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF
AGE, 2008 (THOUSANDS) 14
TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS
OF AGE BY REGION, 2008 (000) 15
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET 15
TYPES OF DIAGNOSTIC TESTING 15
FLUORESCENT IMMUNOASSAY (FIA) 16
Direct Fluorescent Antibody Testing (FA) 16
Indirect Fluorescent Antibody Testing (IFA) 16
Chemiluminescent Microparticle Immunoassay (CIA) 16
ENZYME IMMUNOASSAY (EIA) 16
Basic EIA 17
Enzyme-Linked Immunosorbent Assay (ELISA) 17
GENE PROBE ANALYSIS 17
Polymerase Chain Reaction Amplification (PCR) 18
Nucleic Acid Amplification Test (NAT) 18
Transcription-Mediated Amplification (TMA) 18
Nucleic Acid Sequence-Based Amplification (NASBA) 19
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS 19
TABLE 4 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 19
GLOBAL INFECTIOUS DISEASE VACCINE MARKET 19
TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE
PRODUCTS, THROUGH 2017 ($ MILLIONS) 20
THE GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET 20
TABLE 6 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 20
PROJECTIONS FOR GLOBAL INFECTIOUS DISEASE PRODUCTS BY TYPE AND
DISEASE 21
TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC,
VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 21
VACCINE OPPORTUNITIES 22
CHILDHOOD DISEASES 22
GLOBAL HUMANITARIAN AGENCIES 22
PHARMACEUTICAL OPPORTUNITIES 23
THE EMERGENCE OF GENE THERAPY 23
MERGERS AND ACQUISITIONS 24
TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 ($ MILLIONS) 24

CHAPTER 4 VACCINES-THE PRESENT AND THE FUTURE 26

MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES 26
TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES,
THROUGH 2017 ($ MILLIONS) 26
TYPES OF VACCINES 27
LIVE ATTENUATED VACCINE 27
INACTIVATED VACCINE 27
Acellular/Subunit Vaccines 27
IMMUNITY 27
INNATE IMMUNITY 28
ACQUIRED IMMUNITY 28
The Activity of T Cells 28
Acquired Immunity-Cell-Mediated Response 29
LASTING IMMUNITY 29
VIRAL DISEASES PREVENTED BY VACCINE 29
TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 29
BACTERIAL DISEASES PREVENTED BY VACCINE 30
TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 30
VACCINATION SCHEDULES FOR CHILDREN 30
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS 31
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6
YEARS 31
TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7
TO 18 32
CONCERNS REGARDING VACCINATION IN CHILDHOOD 32
NUMBER OF INOCULATIONS 32
RECOGNIZING IMMUNE RESPONSE 32
IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS 33
VACCINE PRODUCTION 33
FIGURE 2 VACCINE MANUFACTURING PROCESS 33
VACCINE MANUFACTURERS 34
TOP- SELLING VACCINES OF 2011 35
TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION,
MANUFACTURER AND REVENUE, 2011 35
REGIONAL ANALYSIS 35
TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 ($
MILLIONS) 35
FIGURE 3 PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND
2017 36
THE AMERICAS 37
TABLE 17 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY
REGION, THROUGH 2017 ($ MILLIONS) 37
TABLE 18 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY
DISEASE, THROUGH 2017 ($ MILLIONS) 38
EMRA 38
TABLE 19 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY REGION, THROUGH 2017 ($ MILLIONS) 38
TABLE 20 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 39
ASIA 39
TABLE 21 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY REGION, THROUGH 2017 ($ MILLIONS) 39
TABLE 22 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 40
TRENDS IN VACCINE DEVELOPMENT 40
COMBINATION VACCINES 40
INHALED OR INTRANASAL VACCINE ADMINISTRATION 40

CHAPTER 5 VIRAL INFECTIOUS DISEASES 43

GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS 43
TABLE 23 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 43
HEPATITIS B AND C 43
TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 44
RISK FACTORS 44
TREATMENTS 44
HERPES SIMPLEX VIRUS 45
TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 45
INCIDENCE 45
DIAGNOSIS 46
TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES
BY BRAND NAME, TYPE AND MANUFACTURER, 2012 46
TREATMENT 47
TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME
AND MANUFACTURER 47
HEPATITIS B AND C 48
TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 48
DIAGNOSIS 48
TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF
TEST AND REVENUES, 2011 ($ MILLIONS/%) 48
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND
C BY BRAND NAME AND MANUFACTURER, 2012 49
Automated Infectious Disease Testing for Hepatitis 50
TREATMENT MARKET 50
TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING,
BY REVENUES, 2011 ($ MILLIONS) 51
FIGURE 4 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET
AND THEIR MARKET SHARE, 2011 (%) 51
TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012 52
HIV/AIDS 52
TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 53
RISK FACTORS 53
INCIDENCE/MORTALITY 54
HAART TREATMENT 54
HAART Failure 55
Mega-HAART 55
HIV TREATMENT FOR INFANTS 55
HUMAN PAPILLOMAVIRUS 55
HPV AND CANCER 55
INCIDENCE 56
SYMPTOMS 56
DIAGNOSIS 56
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND
NAME, TYPE AND MANUFACTURER, 2012 57
TREATMENT 57
TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME,
AND MANUFACTURER 57
INFLUENZA A AND B 57
VACCINE 58
TREATMENT 58
MEASLES 58
PNEUMONIA 58
BACTERIAL PNEUMONIA 58
Vaccine 59
Treatment 59
VIRAL PNEUMONIA 59
Treatment 59
ROTAVIRUS 59
DEHYDRATION 60
ZINC 60
RSV 60
SYMPTOMS 60
DIAGNOSTIC PRODUCTS 61
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND
TYPE 2012 61
VIRAL DIAGNOSTIC PRODUCTS 61
TABLE 37 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 62
VIRAL PHARMACEUTICAL PRODUCTS 62
TABLE 38 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 62
REGIONAL ANALYSIS 63
TABLE 39 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($
MILLIONS)
63
FIGURE 5 PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND
PHARMACEUTICAL MARKETS BY REGIONS, 2012 AND 2017 (%) 63
TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION,
THROUGH 2017 ($ MILLIONS) 64
TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY
REGION, THROUGH 2017 ($ MILLIONS) 65
AMERICAS 65
Hepatitis B in the U.S. 65
Hepatitis C in the U.S. 66
Hepatitis in Canada 66
Market for Viral Infectious Disease Products in the Americas 66
TABLE 42 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 66
TABLE 43 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 67
Americas Diagnostic and Pharmaceutical Products Market, by
Disease 67
TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC
AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 67
EMRA 67
Hepatitis B, C in EMRA 67
Hepatitis in Africa 68
Hepatitis in Russia, Eurasia 68
Market for Viral Infectious Disease Diagnostic and Pharmaceutical
Products 68
TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC
PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 68
TABLE 46 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 69
EMRA Market for Infectious Disease Diagnostic and Pharmaceutical
Products, by Disease 69
TABLE 47 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 70
ASIA 70
Hepatitis in Asian Region 70
Hepatitis in Japan 70
Hepatitis in China 70
Hepatitis in India 71
TABLE 48 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 71
TABLE 49 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 71
TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 72

CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC
RESISTANCE 74

NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 74
TABLE 51 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES 74
MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS 74
TABLE 52 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 75
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS 75
TABLE 53 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTICS, THROUGH 2017 ($ MILLIONS) 75
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS 76
TABLE 54 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES
PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 76
NOTABLE BACTERIAL DISEASES 76
CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA
PERTUSSIS 76
Diphtheria 76
Tetanus 77
Pertussis 77
MENINGITIS 77
MYCOBACTERIUM TUBERCULOSIS (TB) 78
TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND
PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 78
EPIDEMIOLOGY OF TB 78
GEOGRAPHIC PREVALENCE 79
TABLE 56 PROJECTED MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL
PRODUCTS, BY REGION, THROUGH 2017 ($ MILLIONS) 79
FINANCING CONTROL EFFORTS 80
ANTIBIOTIC DEVELOPMENT 80
TABLE 57 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL 80
TABLE 58 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION 81
ANTIBIOTIC RESISTANCE 81
MECHANISMS OF RESISTANCE 82
METHODS OF RESISTANCE 83
Beta-Lactamase Production 83
Importing Resistance from Other Organisms 83
Examples of Antibiotic-Resistant Bacteria 84
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness 84
Antibiotic Discharge 84
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 85
FAILURE TO FINISH ANTIBIOTIC COURSES 85
ANTIBIOTIC OVERUSE 85
AGRICULTURAL PRACTICES 85
TABLE 59 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS IN
2009, BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL (POUNDS/%) 86
PATIENT PRESSURE 86
INTERNATIONAL SURVEILLANCE OF ANTIBIOTIC-RESISTANT ORGANISMS 87
RESISTANCE BY CLASS OF ANTIBIOTIC 87
TABLE 60 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 87
INCIDENCES OF ANTIBIOTIC RESISTANCE 87
ANTIBIOTIC RESISTANCE IN EUROPE 87
ANTIBIOTIC RESISTANCE IN THE U.S. 88
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS 88
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) 88
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 88
CLOSTRIDIUM DIFFICILE (C. DIFFICILE) 89
REGIONAL ANALYSIS 89
TABLE 61 PROJECTED GLOBAL MARKET FOR BACTERIAL DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 89
FIGURE 6 MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017 (%) 89
THE AMERICAS 90
TABLE 62 PROJECTED AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND
PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 91
Bacterial Infection Diagnostic Product Market in the Americas 91
TABLE 63 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN
THE AMERICAS BY REGION, THROUGH 2017 ($ MILLIONS) 91
Bacterial Infection Pharmaceutical Market in the Americas 91
TABLE 64 BACTERIAL INFECTION PHARMACEUTICAL PRODUCT MARKET IN THE
AMERICAS, BY REGION, THROUGH 2017 ($ MILLIONS) 91
Americas Bacterial Infectious Diseases Diagnostic and
Pharmaceutical Market, by Disease 92
TABLE 65 PROJECTED AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($
MILLIONS)
92
EMRA 93
TABLE 66 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 93
Bacterial Infectious Diseases Diagnostic Market in EMRA 93
TABLE 67 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN
EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 94
Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA 94
TABLE 68 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET
IN EMRA BY REGION, THROUGH 2017 ($ MILLIONS) 94
EMRA Bacterial Infectious Diseases Diagnostic and Pharmaceutical
Market, by Disease 94
TABLE 69 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY DISEASE, THROUGH 2017 ($
MILLIONS)
94
ASIA 95
TABLE 70 PROJECTED ASIA MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 96
Bacterial Infectious Diseases Diagnostic Product Market in Asia 96
TABLE 71 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN
ASIA BY REGION, THROUGH 2017 ($ MILLIONS) 96
Bacterial Infectious Diseases Pharmaceutical Product Market in Asia 97
TABLE 72 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET
IN ASIA, BY REGION, THROUGH 2017 ($ MILLIONS) 97
Asian Bacterial Infectious Diseases Diagnostic and Pharmaceutical
Market, by Disease 97
TABLE 73 PROJECTED ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($
MILLIONS)
97

CHAPTER 7 PARASITIC INFECTIOUS DISEASES 99

NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 99
TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES 99
CLIMATE CHANGE AND VECTOR-BORNE DISEASES 99
MALARIA 100
INCIDENCES OF MALARIA 100
TABLE 75 ESTIMATED 2010 GLOBAL MALARIA CASES AND ESTIMATED DEATHS,
RATE OF DECREASE OF MALARIA DEATHS SINCE 2000, BY REGION* 101
CAUSES OF MALARIA 101
SYMPTOMS OF MALARIA 101
GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND
PHARMACEUTICAL TREATMENTS 101
TABLE 76 PROJECTED GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC
AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 102
INTERVENTIONAL TECHNIQUES TO MINIMIZE EXPOSURE TO MALARIAL
VECTORS 102
TABLE 77 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS,
THROUGH 2017 ($ MILLIONS) 102
DIAGNOSIS OF MALARIA 103
TABLE 78 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS,
THROUGH 2017 ($ MILLIONS) 103
TREATMENT OF MALARIA 103
TABLE 79 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH
TREATMENT AND MANUFACTURER, 2012 104
TABLE 80 PROJECTED GLOBAL MARKET FOR MALARIAL DRUG TREATMENTS,
THROUGH 2017 ($ MILLIONS) 104
REGIONAL ANALYSIS 104
REGIONAL ANALYSIS 105
TABLE 81 PROJECTED GLOBAL MARKET FORMAL ARIAL PREVENTION, DIAGNOSTIC
AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 105
FIGURE 7 GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND
2017 (%) 105
THE AMERICAS 106
TABLE 82 PROJECTED AMERICAS MARKET FOR MALARIAL PREVENTION,
DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 107
Malarial Prevention Product Market in the Americas 107
TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION,
THROUGH 2017 ($ MILLIONS) 107
Malarial Diagnostic Product Market in the Americas 107
TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION,
THROUGH 2017 ($ MILLIONS) 108
Malarial Pharmaceutical Market in the Americas 108
TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY
REGION, THROUGH 2017 ($ MILLIONS) 108
EMRA 108
TABLE 86 PROJECTED EMRA MARKET FOR MALARIAL PREVENTIVE, DIAGNOSTIC
AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 109
Malarial Prevention Market in the EMRA 109
TABLE 87 MALARIAL PREVENTIVE PRODUCT MARKET IN EMRA, BY REGION,
THROUGH 2017 ($ MILLIONS) 109
Malarial Diagnostic Product Market in EMRA 109
TABLE 88 MALARIAL DIAGNOSTIC PRODUCT MARKET IN EMRA, BY REGION,
THROUGH 2017 ($ MILLIONS) 110
Malarial Pharmaceutical Product Market in the EMRA 110
TABLE 89 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA, BY
REGION, THROUGH 2017 ($ MILLIONS) 110
ASIA 110
TABLE 90 PROJECTED ASIA MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC,
AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 ($ MILLIONS) 111
TABLE 91 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION,
THROUGH 2017 ($ MILLIONS) 111
TABLE 92 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION,
THROUGH 2017 ($ MILLIONS) 112
TABLE 93 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION,
THROUGH 2017 ($ MILLIONS) 112
TABLE 94 CURRENT ANT PARASITIC PHARMACEUTICALS WITH TRADENAME,
GENERIC NAME, MANUFACTURER, AND AREA OF TREATMENT, 2012 113
MARKET FOR ANTIPARASITIC PHARMACEUTICALS 113

CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS 115

HEPATITIS C 115
POLYMERASE 115
Vertex Pharmaceuticals 115
NS5B 115
Roche 115
Boehringer Ingelheim 115
INFLUENZA 115
VAXINNATE 116
HSV 116
MALARIA 117
VACCINE 117
PHARMACEUTICALS 117
DIAGNOSTIC TESTING 117
ANTIBIOTIC RESISTANCE 118
GALAPAGOS NV 118
TRIUS THERAPEUTICS 118
CRESTONE PHARMA 119
BASILEA PHARMACEUTICA 119
POLYPHOR 119
REMPEX PHARMA 119
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 120
TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY
DISEASE, 2012 120

CHAPTER 9 PATENT ANALYSIS 128

PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY,
DESCRIPTION AND APPROVAL DATE 128
TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY
PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL
DATE, FEBRUARY 2006 TO FEBRUARY 2013
129
DIAGNOSTIC PATENTS ISSUED, BY COMPANY, APPROVAL DATE, AND DISEASE 141
TABLE 97 INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER,
DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH
2005-DECEMBER 2012
142
PATENTS ISSUED BY COMPANY 142
TABLE 98 INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC
PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013 143
PATENTS ISSUED BY COUNTRY 144
TABLE 99 INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT
PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013 (NUMBER/%) 145
FIGURE 8 NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND
TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013 (%) 146
INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE 146
TABLE 100 PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF
INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013 (NUMBER/%) 146
FIGURE 9 INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL
PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012, (%) 147
INFECTIOUS DISEASES PATENTS, BY YEAR 147
TABLE 101 NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013 148

CHAPTER 10 COMPANY PROFILES 150

ABBOTT LABORATORIES 150
BUSINESS OVERVIEW 150
PRODUCTS 150
TABLE 102 ABBOTT PHARMACEUTICAL PRODUCTS 150
DIAGNOSTIC PRODUCTS 151
TABLE 103 ABBOTT DIAGNOSTIC PRODUCTS 151
ALERE 151
BUSINESS OVERVIEW 151
PRODUCTS 152
TABLE 104 ALERE DIAGNOSTIC PRODUCTS 152
ALFA SCIENTIFIC DESIGNS 153
BUSINESS OVERVIEW 153
PRODUCTS 153
TABLE 105 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS 153
ATLAS LINK BIOTECH CO., LTD. 154
BUSINESS OVERVIEW 154
PRODUCTS 154
TABLE 106 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS 154
ASTRA ZENECA 155
BUSINESS OVERVIEW 155
PRODUCTS 155
TABLE 107 ASTRA ZENECA PHARMACEUTICAL PRODUCTS 155
BAXTER HEALTHCARE 155
BUSINESS OVERVIEW 155
PRODUCTS 156
TABLE 108 BAXTER PHARMACEUTICAL PRODUCTS 156
BAYER AG 156
BUSINESS OVERVIEW 156
PRODUCTS 156
TABLE 109 BAYER PHARMACEUTICAL PRODUCTS 156
BECTON DICKINSON 157
BUSINESS OVERVIEW 157
PRODUCTS 157
TABLE 110 BECTON DICKINSON DIAGNOSTIC PRODUCTS 157
BIO-RAD LABORATORIES 157
BUSINESS OVERVIEW 157
PRODUCTS 158
TABLE 111 BIORAD DIAGNOSTIC PRODUCTS 158
BOEHRINGER INGELHEIM GMBH 158
BUSINESS OVERVIEW 158
PRODUCTS 159
TABLE 112 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS 159
BRISTOL-MYERS SQUIBB COMPANY 159
BUSINESS OVERVIEW 159
PRODUCTS 159
TABLE 113 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS 159
CEPHEID 160
BUSINESS OVERVIEW 160
PRODUCTS 160
TABLE 114 CEPHEID DIAGNOSTIC PRODUCTS 160
CRUCELL NV 160
BUSINESS OVERVIEW 161
PRODUCTS 161
TABLE 115 CRUCELL VACCINE PRODUCTS 161
CUBIST PHARMACEUTICALS 162
BUSINESS OVERVIEW 162
PRODUCTS 162
TABLE 116 CUBIST PHARMACEUTICAL PRODUCT 162
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC. 162
BUSINESS OVERVIEW 162
PRODUCTS 163
TABLE 117 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC
PRODUCTS 163
DIASORIN 163
BUSINESS OVERVIEW 164
PRODUCTS 164
TABLE 118 DIAGNOSTIC PRODUCTS 164
ENANTA PHARMACEUTICALS 164
BUSINESS OVERVIEW 164
ENZO BIOCHEM 165
BUSINESS OVERVIEW 165
PRODUCTS 165
TABLE 119 ENZO BIOCHEM DIAGNOSTIC PRODUCTS 165
FIRST DIAGNOSTIC LLC 165
BUSINESS OVERVIEW 165
PRODUCTS 166
TABLE 120 FIRST DIAGNOSTIC PRODUCTS 166
GILEAD SCIENCES INC. 166
BUSINESS OVERVIEW 166
PRODUCTS 167
TABLE 121 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS 167
GLAXOSMITHKLINE 167
BUSINESS OVERVIEW 167
PRODUCTS 168
TABLE 122 GLAXOSMITHKLINE PHARMACEUTICAL/VACCINE PRODUCTS 168
HOLOGIC GEN-PROBE INC. 169
BUSINESS OVERVIEW 169
PRODUCTS 169
TABLE 123 HOLOGIC/GENPROBE DIAGNOSTIC PRODUCTS 169
HOME ACCESS HEALTH INC. 169
BUSINESS OVERVIEW 170
PRODUCTS 170
TABLE 124 HOME ACCESS DIAGNOSTIC PRODUCTS 170
IDENIX PHARMACEUTICALS 170
BUSINESS OVERVIEW 170
IMMUNOSTICS 170
BUSINESS OVERVIEW 171
PRODUCTS 171
TABLE 125 IMMUNOSTICS DIAGNOSTIC PRODUCTS 171
IND DIAGNOSTIC INC. 171
BUSINESS OVERVIEW 171
PRODUCTS 172
TABLE 126 IND DIAGNOSTIC PRODUCTS 172
INVERNESS MEDICAL INNOVATIONS (SEE ALERE) 172
IPCA LABORATORIES 172
BUSINESS OVERVIEW 172
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 173
BUSINESS OVERVIEW 173
PRODUCTS 173
TABLE 127 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS 173
MANGALAM DRUGS and ORGANICS LTD. 173
BUSINESS OVERVIEW 173
MEDMIRA INC 174
BUSINESS OVERVIEW 174
PRODUCTS 174
TABLE 128 EDMIRA DIAGNOSTIC PRODUCTS 174
MERCK and COMPANY INC. 174
BUSINESS OVERVIEW 174
PRODUCTS 175
TABLE 129 MERCK VACCINE PRODUCTS 175
TABLE 130 MERCK PHARMACEUTICAL PRODUCTS 175
MERIDIAN BIOSCIENCE 176
BUSINESS OVERVIEW 176
PRODUCTS 176
TABLE 131 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS 176
NOVARTIS CORPORATION 177
BUSINESS OVERVIEW 177
PRODUCTS 178
TABLE 132 NOVARTIS DIAGNOSTIC PRODUCTS 178
TABLE 133 NOVARTIS PHARMACEUTICAL PRODUCTS 178
ORASURE TECHNOLOGIES INC. 178
BUSINESS OVERVIEW 178
PRODUCTS 179
TABLE 134 ORASURE DIAGNOSTIC PRODUCTS 179
ORTHO CLINICAL DIAGNOSTICS 179
BUSINESS OVERVIEW 179
PRODUCTS 179
TABLE 135 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS 179
PARATEK PHARMACEUTICALS 180
BUSINESS OVERVIEW 180
PFIZER INC 180
BUSINESS OVERVIEW 180
PRODUCTS 181
TABLE 136 PFIZER VACCINE PRODUCTS 181
TABLE 137 PFIZER PHARMACEUTICAL PRODUCTS 181
PRINCETON BIOMEDITECH CORPORATION 181
BUSINESS OVERVIEW 181
PRODUCTS 182
TABLE 138 PRINCETON BIOMEDICTECH DIAGNOSTIC PRODUCTS 182
PROTEIN SCIENCES CORPORATION 182
BUSINESS OVERVIEW 182
QUIDEL 183
BUSINESS OVERVIEW 183
PRODUCTS 183
TABLE 139 QUIDEL DIAGNOSTIC PRODUCTS 183
QUIGEN N.V. 183
BUSINESS OVERVIEW 184
PRODUCTS 184
TABLE 140 QUIGEN DIAGNOSTIC PRODUCTS 184
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.) 184
BUSINESS OVERVIEW 184
PRODUCTS 185
TABLE 141 ROCHE DIAGNOSTIC PRODUCTS 185
TABLE 142 ROCHE PHARMACEUTICAL PRODUCTS 185
RIB-X PHARMACEUTICALS 185
BUSINESS OVERVIEW 185
ROMARK LABORATORIES 186
BUSINESS OVERVIEW 186
SANOFI PASTEUR 186
BUSINESS OVERVIEW 186
PRODUCTS 187
TABLE 143 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS 187
SCICLONE PHARMACEUTICALS 187
BUSINESS OVERVIEW 187
PRODUCTS 188
TABLE 144 SCICLONE PHARMACEUTICAL PRODUCTS 188
SHANGHAI KEHUA BIO-ENGINEERING CO., LTD. 188
BUSINESS OVERVIEW 188
PRODUCTS 188
TABLE 145 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS 188
STANDARD DIAGNOSTICS INC 189
BUSINESS OVERVIEW 189
PRODUCTS 189
TABLE 146 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS 189
TETRAPHASE PHARMACEUTICALS 190
TRINITY BIOTECH PLC 190
BUSINESS OVERVIEW 190
PRODUCTS 191
TABLE 147 TRINITY BIOTECH DIAGNOSTIC PRODUCTS 191
VERTEX PHARMACEUTICALS 191
BUSINESS OVERVIEW 191
PRODUCTS 192
TABLE 148 VERTEX PHARMACEUTICAL PRODUCTS 192
VIIV HEALTHCARE 192
BUSINESS OVERVIEW 192
PRODUCTS 193
TABLE 149 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS 193



LIST OF TABLES

SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC,
VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 ($ MILLIONS) 7
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME
LEVEL (%) 11
TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER OF
CASES, TREATMENT OPTIONS) 11
TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS OF
AGE BY REGION, 2008 (000) 15
TABLE 4 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 19
TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE
PRODUCTS, THROUGH 2017 ($ MILLIONS) 20
TABLE 6 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 20
TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC,
VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 ($ MILLIONS) 21
TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 ($ MILLIONS) 24
TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES,
THROUGH 2017 ($ MILLIONS) 26
TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 29
TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES 30
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS 31
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6
YEARS 31
TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO
18 32
TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION,
MANUFACTURER AND REVENUE, 2011 35
TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 ($
MILLIONS) 35
TABLE 17 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY
REGION, THROUGH 2017 ($ MILLIONS) 37
TABLE 18 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY
DISEASE, THROUGH 2017 ($ MILLIONS) 38
TABLE 19 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY REGION, THROUGH 2017 ($ MILLIONS) 38
TABLE 20 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 39
TABLE 21 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY REGION, THROUGH 2017 ($ MILLIONS) 39
TABLE 22 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES,
BY DISEASE, THROUGH 2017 ($ MILLIONS) 40
TABLE 23 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 43
TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 44
TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 45
TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES
BY BRAND NAME, TYPE AND MANUFACTURER, 2012 46
TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND
MANUFACTURER 47
TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 48
TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF
TEST AND REVENUES, 2011 ($ MILLIONS/%) 48
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C
BY BRAND NAME AND MANUFACTURER, 2012 49
TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY
REVENUES, 2011 ($ MILLIONS) 51
TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012 52
TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 53
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND
NAME, TYPE AND MANUFACTURER, 2012 57
TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME,
AND MANUFACTURER 57
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND
TYPE 2012 61
TABLE 37 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS, THROUGH 2017 ($ MILLIONS) 62
TABLE 38 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS, THROUGH 2017 ($ MILLIONS) 62
TABLE 39 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($
MILLIONS)
63
TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION,
THROUGH 2017 ($ MILLIONS) 64
TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY REGION,
THROUGH 2017 ($ MILLIONS) 65
TABLE 42 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE
DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 66
TABLE 43 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE
PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 67
TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND
PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 ($ MILLIONS) 67
TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC
PRODUCTS BY REGION, THROUGH 2017 ($ MILLIONS) 68
TABLE 46 PROJECTE

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.